Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 90, Issue 6, Pages 774-776Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2011.222
Keywords
-
Categories
Ask authors/readers for more resources
Clopidogrel is an important antiplatelet agent, but a considerable variability in the biological effect of the drug has been observed. Additionally, patients with insufficient platelet reactivity inhibition following a loading dose (LD) of clopidogrel have a poor outcome. The mechanisms of variability are dependent on genetic polymorphisms of enzymes involved in clopidogrel metabolism. Paraoxonase 1 has been identified as the main determinant of the biological and clinical efficacy of clopidogrel. This finding could enable the use of pharmacogenomics to tailor antiplatelet agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available